Objective Mucous membrane pemphigoid (MMP) is an autoimmune blistering disorder with
tendency to scarring. Long term immunosuppressive treatment may be required to minimize …

Pemphigus vulgaris (PV) is an auto-immune blistering skin disease characterized by flaccid
blisters and painful erosions of mucous membranes and skin. Suprabasal blister formation …

Rituximab is a chimeric monoclonal antibody against CD20 that mediates B-cell depletion. It
has been shown to be effective in a variety of autoimmune-related diseases, including …

BACKGROUND: Rituximab (RTX) has been shown to be effective and safe for short-term
treatment of severe pemphigus. Its long-term results remain unknown. OBJECTIVE: We …

Five patients were female and the mean age at the start of rituximab treatment was 57.6
years (range 39-80). The mean duration of disease before rituximab therapy was 53.4 …

Pemphigus is a serious autoimmune disease with few appropriate therapeutic options.
Although rituximab (RTX) has recently shown great promise in this regard, the best protocol …

[Rituximab induced remission of pemphigus vulgaris: 2 cases]. - Abstract - Europe PMC Sign
in | Create an account https://orcid.org Europe PMC Menu About Tools Developers Help …

Rituximab targets the B-lymphocyte antigen CD20, providing pemphigus vulgaris patients
with long-term remissions. However, the effects of repeated courses have not yet been …

BACKGROUND: Pemphigus vulgaris (PV) is a blistering autoimmune bullous disease that is
usually fatal without proper treatment. There are no clear treatment guidelines for PV at this …

Rituximab is a chimeric monoclonal antibody against the B-cell CD20 antigen, and has
shown efficacy in the treatment of autoimmune bullous dermatoses, including bullous …